Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10412899 | 0.86 | NPC1 (0.66) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568295 | 0.82 | CYP19A1 (0.58) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL12124985 | 0.82 | NPC1 (0.75) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568274 | 0.80 | NPC1 (0.58) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568269 | 0.80 | NPC1 (0.53) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568267 | 0.78 | CCNB2 (0.39) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568268 | 0.78 | NPC1 (0.50) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568291 | 0.77 | NPC1 (0.53) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568263 | 0.76 | NPC1 (0.54) | ALDH1A1KDM4ELMNANPC1RAB9A | |
| SCHEMBL4568254 | 0.76 | RAB9A (0.57) | ALDH1A1KDM4ELMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| CN-101087758-B | Indole derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA NV | 2012-06-06 | — | — | CN | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-1809602-B1 | INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-7345084-B2 | Indole derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-18 | — | — | US | disclosed |
| CN-101087758-A | Indole derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| US-20070135511-A1 | INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | JIANG WEIQIN | 2007-06-14 | — | — | US | disclosed |
| US-7183309-B2 | Indole derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20060111427-A1 | Indole derivatives useful as progesterone receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | ALDH1A1 422/4885KDM4E 3521/4885LMNA 4472/4885 |
| US-20070135511-A1 | INDOLE DERIVATIVES USEFUL AS PROGESTERONE RECEPTOR MODULATORS | PRLHR, GNRHR, ADCYAP1R1 | ALDH1A1 2636/4885KDM4E 2888/4885LMNA 1228/4885 |
| US-20060111427-A1 | Indole derivatives useful as progesterone receptor modulators | PRLHR, GNRHR, ADCYAP1R1 | ALDH1A1 2636/4885KDM4E 2888/4885LMNA 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.